Table 3.

Surgical details

	Ustekinumab cohort (n=20)	Anti-TNF cohort (n=40)	P value
Indication of surgery:
Medical refractory disease	^5 (25%)	^^3 (7.5%)	0.19
Obstruction	12 (60%)	26 (65%)
Free bowel perforation	2 (10%)	2 (5%)
Intraabdominal abscess	0	2 (5%)
Closure of ostomy	0	3 (7.5%)
Others	*1 (5%)	**4 (10%)
Nature of surgery:
Emergency	11 (55%)	10 (25%)	0.04
Open laparotomy	13 (65%)	20 (50%)	0.40
Type of surgery (n,%):  Ileal resection	6 (30%)	9 (22.5%)	0.54
Ileocolonic resection	7 (35%)	17 (42.5%)	0.78
Subtotal colectomy	4 (20%)	3 (7.5%)	0.21
Proctocolectomy	2 (10%)	0	0.10
Ostomy	14 (70%)	5 (12.5%)	<0.001
Primary anastomosis	9 (45%)	26 (65%)	0.17
Stricturoplasty	1 (5%)	2 (5%)	1.00
Fistula repair	2 (10%)	3 (7.5%)	1.99
Hernia repair	1 (5%)	1 (2.5%)	1.00
Cholecystectomy  Appendectomy	1 (5%) 0	4 (10%) 1 (2.5%)	0.66 1.00
Adhesiolysis	0	7 (17.5%)	0.08

^inflammatory (ileo)colitis refractory to treatment x5

^^ inflammatory colitis refractory to treatment x 2, defunctioning loop ileostomy for refractory perianal disease x1

*cholecystectomy for cholecystitis

**cholecystectomy for porcelain gallbladder; cholecystectomy for gall bladder cancer; cholecystectomy for biliary colic x2